| Stereochemistry | ABSOLUTE |
| Molecular Formula | C73H111N17O21.2ClH |
| Molecular Weight | 1635.6884 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.[H][C@@]1(NC(=O)[C@H](CO)NC(=O)C[C@@H](CCCC(C)C)OC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](CCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC4=CC=CC=C4)N(C)C(=O)CNC(=O)[C@H](CO)NC1=O)[C@@H](O)C(N)=O
InChI
InChIKey=VBXUDTFBJRKXBU-JCBBIFMDSA-N
InChI=1S/C73H111N17O21.2ClH/c1-38(2)17-14-20-43-32-56(94)80-53(37-92)69(106)88-59(61(98)62(77)99)71(108)87-52(36-91)63(100)79-35-57(95)89(7)54(30-41-18-10-9-11-19-41)70(107)86-49(29-39(3)4)66(103)81-46(23-15-27-74)64(101)82-47(25-26-58(96)97)65(102)85-51(33-55(76)93)68(105)84-50(31-42-34-78-45-22-13-12-21-44(42)45)67(104)83-48(24-16-28-75)72(109)90(8)60(40(5)6)73(110)111-43;;/h9-13,18-19,21-22,34,38-40,43,46-54,59-61,78,91-92,98H,14-17,20,23-33,35-37,74-75H2,1-8H3,(H2,76,93)(H2,77,99)(H,79,100)(H,80,94)(H,81,103)(H,82,101)(H,83,104)(H,84,105)(H,85,102)(H,86,107)(H,87,108)(H,88,106)(H,96,97);2*1H/t43-,46-,47+,48-,49+,50-,51-,52+,53+,54-,59-,60+,61-;;/m1../s1
| Molecular Formula | C73H111N17O21 |
| Molecular Weight | 1562.7666 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.4609 |
| Charge | 0 |
| Count |
MOL RATIO
2 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Lotilibcin (WAP-8294A2) is an antibiotic originally isolated from Lysobacter sp. It is active against methicillin-resistant gram-positive bacteria. Lotilibcin antimicrobial activity is due to lysis of the bacterial membrane, and its membrane-disrupting effect depends on the presence of menaquinone, an essential factor for the bacterial respiratory chain. It was developing for the treatment of susceptible bacterial infections
